More ER Docs Prescribing Meds To Fight Opioid Addiction

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 25, 2025.

By Dennis Thompson HealthDay Reporter

TUESDAY, Feb. 25, 2025 -- More emergency room doctors in California are prescribing the anti-addiction medication buprenorphine, contributing to the state’s battle against the U.S. opioid epidemic, a new study suggests.

About 16% of scrips written for buprenorphine in California came from an ER doctor in 2022, up from only 2% in 2017, researchers reported recently in the Journal of the American Medical Association.

More ER docs also started patients on buprenorphine treatment, with initial prescriptions written by emergency doctors increasing from 0.1% to 5% during the same period, results show.

“We're seeing this huge shift of prescriptions over a five-year period -- the efforts are working,” lead researcher Dr. Annette Dekker, an assistant professor of emergency medicine at UCLA, said in a news release.

This increase is part of an initiative in California called CA Bridge, which since 2019 has worked with more than 80% of the state’s hospitals to make it easier for an ER patient to get a buprenorphine prescription, researchers said in background notes.

“For a lot of people who use opioids, the emergency department might be the only touch point they have with the healthcare system, so it’s a huge window of opportunity to make a difference,” Dekker said.

Buprenorphine binds to opioid receptors in the brain, reducing a person’s cravings for narcotics without producing the euphoric feeling that opioids induce, researchers said.

Despite its effectiveness, an estimated 87% of people with opioid use disorder are never prescribed buprenorphine or any medication to help them fight their addiction, researchers noted.

The CA Bridge program aimed to change that by training ER staff on the use of buprenorphine to treat opioid addiction, they said.

The program also provides navigators to help ER patients find community treatment programs, through which they can keep taking buprenorphine initially prescribed in the ER.

For this study, researchers analyzed records on more than 345,000 patients who received 3.8 million prescriptions for buprenorphine from nearly 22,000 doctors in California between 2017 and 2022.

The number of emergency doctors who prescribed buprenorphine for the first time increased from 70 in 2017 (3%) to 941 in 2022 (25%), results show.

Likewise, the number of patients receiving their first buprenorphine prescription from an ER doc increased from 46 in 2017 to 3,289 in 2022.

An ER doctor’s intervention helped many patients step onto the road to recovery, researchers found.

About 1 in 3 of these patients went on to receive a second prescription of buprenorphine, and 1 in 9 got at least six months of continuous buprenorphine treatment, the study says.

“These data strongly suggest a long-term beneficial impact from emergency department-prescribed buprenorphine for opioid use disorder,” co-researcher Dr. Andrew Herring, program director of the Bridge Center at the Public Health Institute in Oakland, Calif., said in a news release.

“To observe that for every nine patients who start buprenorphine treatment in an emergency department, one achieves six months of continuous treatment within the next year is simply remarkable,” Herring added. “It is a call to action that buprenorphine should be an expected standard of care in all emergency departments in every state.”

These results show that with “adequate state investments, Emergency Departments can play a crucial role for patients with opioid addiction -- being available as a safety net 24 hours a day, 365 days a year, and providing pivotal steps in the cascade of care,” says an accompanying editorial co-written by Dr. Gail D’Onofrio, a professor of emergency medicine at Yale School of Medicine.

“California provides a model and blueprint for other states to follow for both urban and rural areas as we continue to fight this epidemic,” the editorial concluded.

Sources

  • Journal of the American Medical Association, Feb. 19, 2025
  • UCLA, news release, Feb. 19, 2025

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2025-02-26 00:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords